2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 713

NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 382

Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 706

Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments

SLE – Clinical Poster I: Epidemiology & Pathogenesis – ARP

9:00AM-11:00AM: Abstract Number: 379

Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 685

Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 653

Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 184

No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 480

Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 377

Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 28

Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 104

Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 199

Obesity and Incident Opioid Use in Rheumatoid Arthritis

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 470

Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 612

Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 782

Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].